Jointown(SH:600998) Sou Hu Cai Jing·2025-12-30 01:04Core Insights - The article highlights the significant achievements and strategic direction of Jiuzhoutong Group, emphasizing its dual listing and extensive logistics network coverage across China [3][4]. Group 1: Company Achievements - Jiuzhoutong Group participated in a meeting for private enterprises, reflecting the support from the government for business development [3]. - The company has launched a dual listing, becoming the only dual-listed company in the Chinese pharmaceutical industry, with its public REITs debut on February 27 [3]. - Jiuzhoutong celebrated its 40th anniversary with impressive financial results, reporting over 150 billion yuan in revenue for two consecutive years, and operates 687 subsidiaries with a logistics network covering over 96% of administrative regions in China [3]. Group 2: Strategic Initiatives - The company is advancing its "Three New and Two Transformations" strategy, focusing on new products, new retail, new healthcare, digitalization, and real estate securitization [3]. - Jiuzhoutong has been recognized as the 55th in the latest list of China's top 500 private enterprises and ranks 4th in the pharmaceutical commercial industry, leading as the top private pharmaceutical distributor [4].